Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence.
osteoarthritis
pain
tapentadol
Journal
Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
10
2018
accepted:
27
02
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Osteoarthritis (OA) is the most prevalent joint disease in older people worldwide. Pain owing to OA is considered one of the most frequent causes of chronic pain; however, current pharmacological approaches have some limitations in terms of efficacy and safety. Of note, descending inhibitory pain pathways are often disrupted in chronic OA pain, and pharmacotherapies targeting those pathways - eg, those that block norepinephrine reuptake may be more appropriate for managing chronic pain than pure μ-opioid receptor (MOR) agonists. Tapentadol is an analgesic molecule, which combines two synergistic mechanisms of action, MOR, and norepinephrine reuptake inhibition. This narrative review will briefly discuss the mechanisms contributing to the onset and maintenance of pain in OA patients; clinical data on the use of tapentadol in this setting will then be presented and commented.
Identifiants
pubmed: 31190964
doi: 10.2147/JPR.S190161
pii: 190161
pmc: PMC6529616
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1529-1536Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur J Pain. 2006 May;10(4):287-333
pubmed: 16095934
Clin Ther. 2009 Feb;31(2):260-71
pubmed: 19302899
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003115
pubmed: 19821302
Drugs Today (Barc). 2009 Jul;45(7):483-96
pubmed: 19834626
Pain. 2010 Jun;149(3):573-81
pubmed: 20418016
Clin Drug Investig. 2010;30(8):489-505
pubmed: 20586515
Eur J Pain. 2010 Sep;14(8):781-3
pubmed: 20659810
Neurosci Lett. 2012 Jan 24;507(2):151-5
pubmed: 22197547
Arthritis Rheum. 2012 Jul;64(7):2223-32
pubmed: 22246649
Expert Opin Pharmacother. 2012 Jul;13(10):1437-49
pubmed: 22698264
J Pain Res. 2012;5:121-38
pubmed: 22792000
Age Ageing. 2013 May;42(3):272-8
pubmed: 23568255
Clin Drug Investig. 2013 Sep;33(9):607-19
pubmed: 23912473
Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53
pubmed: 23973124
J Am Acad Orthop Surg. 2013 Sep;21(9):577-9
pubmed: 23996989
J Opioid Manag. 2013 Jul-Aug;9(4):281-90
pubmed: 24353022
Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
pubmed: 24462672
Nat Rev Rheumatol. 2014 Jun;10(6):374-80
pubmed: 24686507
BMJ. 2015 Mar 31;350:h1225
pubmed: 25828856
Curr Osteoporos Rep. 2015 Dec;13(6):399-406
pubmed: 26419467
J Opioid Manag. 2015 Sep-Oct;11(5):393-403
pubmed: 26535967
Joints. 2016 Jan 28;3(3):146-50
pubmed: 26889471
Cochrane Database Syst Rev. 2016 Jun 07;(6):CD012230
pubmed: 27271789
BMC Musculoskelet Disord. 2016 Oct 12;17(1):425
pubmed: 27733199
BMC Musculoskelet Disord. 2016 Nov 9;17(1):463
pubmed: 27829422
Br J Pain. 2016 Nov;10(4):217-221
pubmed: 27867511
Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1672-1683
pubmed: 28429337
Curr Med Res Opin. 2017 Aug;33(8):1423-1432
pubmed: 28537501
Curr Med Res Opin. 2017 Aug;33(8):1413-1422
pubmed: 28537506
BMC Anesthesiol. 2017 Jul 11;17(1):91
pubmed: 28693439
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):79-84
pubmed: 28967359
Front Mol Neurosci. 2017 Nov 03;10:349
pubmed: 29163027
PLoS One. 2018 Jan 12;13(1):e0191045
pubmed: 29329325
Rehabil Nurs. 2018 Jan 24;:null
pubmed: 29369113
Eur J Pain. 2018 May;22(5):827-844
pubmed: 29369473
Int J Mol Sci. 2018 Feb 27;19(3):null
pubmed: 29495538
Curr Med Res Opin. 2018 Jul;34(7):1169-1178
pubmed: 29513044